SPAC977.03 Antibody

What is SPAC977.03 and why is it studied in research?

SPAC977.03 is a gene encoding a protein in the fission yeast Schizosaccharomyces pombe (strain 972 / ATCC 24843). According to transcriptome analysis studies, SPAC977.03 appears to be among the genes regulated by the stationary phase-specific transcription factor Phx1. Specifically, it is downregulated in Δphx1 mutants, suggesting its expression is positively affected by Phx1 . This regulation indicates potential roles in stationary phase survival mechanisms and stress responses. The protein has been assigned UniProt number G2TRN8, and studying it may provide insights into stress tolerance mechanisms in yeast cells.

What are the common applications for SPAC977.03 antibody in research?

The commercially available SPAC977.03 antibody has been validated for the following applications:

These applications make the antibody suitable for protein detection, quantification, and expression level analysis in fission yeast research .

How should SPAC977.03 antibody samples be stored and handled?

For optimal stability and activity retention:

• Store at -20°C or -80°C for long-term preservation

• Avoid repeated freeze-thaw cycles which can denature the antibody and reduce its efficacy

• Working aliquots can be prepared and stored separately to minimize freeze-thaw cycles

• When shipping or transporting, maintain cold chain conditions (typically shipped on blue ice)

What components are typically included in a SPAC977.03 antibody kit?

A typical SPAC977.03 antibody kit includes:

• 200μg recombinant antigens (positive control)

• 1ml pre-immune serum (negative control)

• Rabbit polyclonal antibodies purified by Antigen Affinity

This composition allows researchers to run appropriate controls alongside their experiments to validate specificity and sensitivity .

How can I validate the specificity of SPAC977.03 antibody in my experimental system?

Validation should follow a multi-step approach:

• Genetic validation: Test the antibody in wild-type vs. gene deletion (SPAC977.03Δ) strains if available, expecting signal only in wild-type samples.

• Recombinant protein control: Use the supplied recombinant SPAC977.03 protein as a positive control in Western blot or ELISA.

• Pre-immune serum comparison: Compare signals between the antibody and pre-immune serum to identify non-specific binding.

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide to block specific binding sites, which should eliminate specific signals but leave non-specific binding.

• Orthogonal detection methods: Confirm findings using alternative methods such as mass spectrometry or RNA expression analysis.

This comprehensive validation approach aligns with recent calls to standardize antibody validation in research to improve reproducibility .

How does the recombinant production method impact SPAC977.03 antibody characteristics compared to traditional methods?

Recombinant production of antibodies offers several advantages over traditional hybridoma or polyclonal methods:

• Consistency: Recombinant antibodies have defined sequences that eliminate batch-to-batch variation seen in traditional methods. For SPAC977.03 antibody, this ensures reliable detection across experiments .

• Specificity: Modern recombinant approaches allow for selection of the most specific binders from billions of variants, potentially yielding higher specificity than traditional methods .

• Reproducibility: The defined sequence allows other researchers to produce identical antibodies, enhancing reproducibility across different labs.

• Ethical considerations: Reduces or eliminates the need for animal immunization for antibody production.

Traditional polyclonal methods (like those used for current SPAC977.03 antibodies) yield antibody mixtures where only 0.5-5% of antibodies bind to their intended target and functionality varies between batches , which can be problematic for quantitative research applications.

What technical considerations should be addressed when using SPAC977.03 antibody in challenging experimental contexts?

When working with SPAC977.03 antibody in challenging contexts, consider:

• Cell wall interference: S. pombe has a thick cell wall that can impede antibody access in certain applications (e.g., immunofluorescence). Methods to address this include:

  • Optimized spheroplasting protocols using zymolyase or lysing enzymes

  • Extended permeabilization steps (1-2% Triton X-100 for 15-30 minutes)

  • Microwave antigen retrieval for fixed samples

• Cross-reactivity with similar proteins: SPAC977.04 and SPAC977.05c share sequence similarity with SPAC977.03 and may cross-react. To minimize this:

  • Include competition controls with recombinant proteins

  • Perform Western blot analysis to confirm single band detection at the expected molecular weight

  • Consider epitope mapping to identify unique recognition regions

• Post-translational modifications: If SPAC977.03 undergoes modifications like phosphorylation (as seen with other yeast proteins ), this may affect epitope recognition. Validate detection across different cell cycle stages or stress conditions.

How can I optimize immunoprecipitation protocols with SPAC977.03 antibody for protein-protein interaction studies?

For effective immunoprecipitation:

• Buffer optimization:

  • Start with standard IP buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 1% NP-40, protease inhibitors)

  • For membrane proteins, add 0.1-0.5% SDS or 0.5-1% Triton X-100

  • Include phosphatase inhibitors if studying phosphorylation states

• Antibody coupling:

  • Direct coupling to beads (e.g., Protein A/G) can reduce background

  • Use 2-5μg antibody per 500μg of protein lysate

  • Pre-clear lysates with beads alone to reduce non-specific binding

• Controls:

  • Include IP with pre-immune serum as negative control

  • If possible, perform parallel IP from SPAC977.03Δ strain

  • Include input, unbound, and IP fractions in analysis

• Crosslinking considerations:

  • For transient interactions, consider using crosslinkers like DSP or formaldehyde

  • For yeast applications, in vivo crosslinking before cell lysis may help preserve complexes

What approaches can detect conflicting results between SPAC977.03 antibody signal and gene expression data?

When antibody-based protein detection conflicts with gene expression data:

• Verify antibody specificity: Re-validate using the approaches in FAQ 2.1 to rule out cross-reactivity or non-specific binding.

• Post-transcriptional regulation: Investigate possible mechanisms affecting protein levels independent of mRNA:

  • Analyze protein stability using cycloheximide chase experiments

  • Examine ubiquitination status using ubiquitin-specific antibodies in IP experiments

  • Investigate miRNA regulation if applicable to your system

• Technical considerations:

  • Ensure appropriate normalization in both protein and RNA quantification

  • Verify RNA integrity in gene expression experiments

  • Check for potential protein degradation in sample preparation

• Biological timing: Consider time lags between transcription and translation, especially important in stress response studies where SPAC977.03 may be regulated .

• Cross-platform validation: Use orthogonal methods like mass spectrometry to independently quantify protein levels.

What are the most common causes of weak or absent signal when using SPAC977.03 antibody in Western blotting?

When facing weak or no signal:

• Protein expression levels: SPAC977.03 may have condition-dependent expression. Ensure cells are grown under conditions that promote expression (consider stationary phase given its Phx1 regulation ).

• Extraction efficiency:

  • For yeast proteins, use glass bead lysis or enzymatic cell wall digestion to ensure complete protein release

  • Include appropriate detergents (0.1-1% SDS, NP-40, or Triton X-100) to solubilize membrane proteins

  • Prevent protein degradation by maintaining samples at 4°C and using protease inhibitors

• Transfer efficiency:

  • Optimize transfer conditions for the protein's molecular weight

  • Consider semi-dry vs. wet transfer depending on protein size

  • Verify transfer by Ponceau S staining

• Antibody conditions:

  • Test different dilutions (typically 1:500 to 1:5000)

  • Extend primary antibody incubation (overnight at 4°C)

  • Check antibody storage conditions and expiration

• Detection systems:

  • For low abundance proteins, use high-sensitivity ECL substrates or fluorescent detection

  • Consider signal amplification methods if necessary

How might cellular stress conditions affect SPAC977.03 detection in experimental systems?

Stress conditions may significantly impact SPAC977.03 detection:

• Expression level changes: As SPAC977.03 appears to be regulated by the stress-responsive transcription factor Phx1 , its expression may vary significantly under different stress conditions:

  • Stationary phase (nutrient limitation)

  • Oxidative stress

  • Heat shock

  • Heavy metal exposure (particularly cadmium, as related genes are regulated by Phx1)

• Protein modifications: Stress may induce post-translational modifications that alter epitope accessibility:

  • Phosphorylation (common in stress responses)

  • Ubiquitination (potentially leading to degradation)

  • Glycosylation changes

• Subcellular localization: Stress might alter protein localization, affecting extraction efficiency with different lysis protocols.

• Experimental approach:

  • Include appropriate stress control samples

  • Consider time-course experiments to capture dynamic responses

  • Use fractionation techniques if localization changes are suspected

What are effective approaches for detecting low-abundance SPAC977.03 protein in complex samples?

To enhance detection of low-abundance SPAC977.03:

• Sample enrichment:

  • Perform subcellular fractionation to concentrate the compartment where SPAC977.03 resides

  • Use immunoprecipitation to concentrate the protein before analysis

  • Consider affinity purification techniques using tagged versions of the protein

• Signal amplification:

  • Implement tyramide signal amplification (TSA) for immunofluorescence

  • Use ultra-sensitive chemiluminescent substrates for Western blotting

  • Consider proximity ligation assay (PLA) for in situ detection

• Alternative detection platforms:

  • Use mass spectrometry with targeted multiple reaction monitoring (MRM)

  • Implement digital ELISA platforms with single-molecule detection capability

  • Consider protein arrays for high-sensitivity detection

• Genetic approaches:

  • Create tagged versions of SPAC977.03 (GFP, FLAG, HA) if direct detection proves difficult

  • Use overexpression systems when native detection is challenging but verify physiological relevance

How should researchers interpret unexpected additional bands when using SPAC977.03 antibody in Western blotting?

When encountering unexpected bands:

• Systematic investigation:

  • Document molecular weights of all bands

  • Compare pattern across different sample types and conditions

  • Test specificity with blocking peptides for each band

• Potential explanations:

  • Post-translational modifications: Phosphorylation, glycosylation, or ubiquitination can cause mobility shifts

  • Protein isoforms: Check genome databases for alternative splice variants

  • Proteolytic fragments: Include additional protease inhibitors in sample preparation

  • Cross-reactivity: Verify against related proteins like SPAC977.04 and SPAC977.05c which show sequence similarity

  • Sample degradation: Prepare fresh samples with appropriate handling

• Validation approaches:

  • Perform mass spectrometry analysis of the unexpected bands

  • Test antibody in knockout/knockdown systems if available

  • Use orthogonal antibodies targeting different epitopes of SPAC977.03

What strategies can determine if SPAC977.03 undergoes stress-induced post-translational modifications?

To investigate potential PTMs:

• Modification-specific detection:

  • Use Phos-tag SDS-PAGE to detect phosphorylated forms

  • Employ glycosylation-specific stains (PAS-Silver) for glycoproteins

  • Perform ubiquitin immunoblotting after SPAC977.03 immunoprecipitation

• Enzymatic treatments:

  • Compare mobility before and after phosphatase treatment

  • Use deglycosylation enzymes (EndoH, PNGase F) to identify glycosylated forms

  • Apply ubiquitin-specific proteases to confirm ubiquitination

• Mass spectrometry approaches:

  • Perform IP-MS with SPAC977.03 antibody

  • Use targeted approaches to identify specific modifications

  • Implement SILAC or TMT labeling to quantify modification changes under stress

• Site-directed mutagenesis:

  • Mutate predicted modification sites and observe effects on protein mobility and function

  • Create phosphomimetic mutations to assess functional consequences

How can researchers utilize SPAC977.03 antibody in chromatin immunoprecipitation (ChIP) experiments if the protein has potential DNA-binding functions?

For adapting SPAC977.03 antibody to ChIP applications:

• Protocol modifications:

  • Optimize crosslinking conditions (1-3% formaldehyde for 10-20 minutes)

  • Adjust sonication parameters for S. pombe chromatin (typically 10-15 cycles)

  • Use specialized ChIP buffers with appropriate salt concentrations (150-300mM NaCl)

• Controls and validation:

  • Include mock IP with pre-immune serum

  • Use known negative genomic regions for background assessment

  • If possible, perform parallel ChIP in SPAC977.03Δ strain as negative control

• Analysis approaches:

  • Start with ChIP-qPCR of candidate regions before moving to genome-wide methods

  • For ChIP-seq, ensure sufficient sequencing depth (20-30 million reads)

  • Implement appropriate peak calling algorithms suited for yeast genomes

• Addressing potential challenges:

  • If direct ChIP is inefficient, consider tagged versions of SPAC977.03

  • For transient interactions, implement dual crosslinking with DSG before formaldehyde

  • Consider ChIP-exo or CUT&RUN for higher resolution binding site identification

What methodological approaches can link SPAC977.03 protein function to its expression changes during stress responses?

To connect function with expression changes:

• Genetic manipulation:

  • Create conditional expression systems (e.g., nmt1 promoter variants) to mimic stress-induced changes

  • Implement CRISPR interference for partial knockdown to simulate reduced expression

  • Generate point mutants of functional domains to dissect specific activities

• Integrative analysis:

  • Correlate protein levels (via quantitative Western blotting) with stress phenotypes

  • Perform RNA-seq and proteomics in parallel to identify post-transcriptional regulation

  • Use ribosome profiling to assess translation efficiency under stress conditions

• Protein interaction dynamics:

  • Implement BioID or APEX proximity labeling to capture stress-dependent interactors

  • Use FRET or BiFC to visualize interactions in living cells under stress

  • Perform temporal interaction studies during stress response progression

• Localization studies:

  • Track protein localization changes using immunofluorescence with the antibody

  • For dynamic studies, create fluorescent protein fusions if antibody-based approaches are limiting

  • Implement subcellular fractionation followed by immunoblotting to quantify redistribution

How can epitope mapping improve the application of SPAC977.03 antibody in diverse experimental conditions?

Epitope mapping benefits:

• Technical implementation:

  • Create overlapping peptide arrays covering the full SPAC977.03 sequence

  • Test antibody binding against truncation mutants in Western blotting

  • Implement hydrogen-deuterium exchange mass spectrometry for conformational epitopes

  • Use competition assays with synthesized peptides

• Applications of mapping data:

  • Predict conditions where epitope might be masked (e.g., protein-protein interactions)

  • Identify if the epitope contains potential modification sites that could affect recognition

  • Determine if the epitope is in conserved regions for cross-species applications

  • Assess whether the epitope might be accessible in native vs. denatured conditions

• Strategic improvements:

  • Generate complementary antibodies targeting different epitopes

  • Design blocking peptides for enhanced specificity verification

  • Optimize immunoprecipitation conditions based on epitope location and accessibility

What considerations are important when using SPAC977.03 antibody for quantitative comparative studies across different growth conditions or genetic backgrounds?

For rigorous quantitative comparisons:

• Normalization strategies:

  • Implement multiple loading controls (e.g., tubulin, actin, and total protein staining)

  • Consider spike-in standards of known concentration for absolute quantification

  • Use normalization to cell number when comparing different growth conditions

• Technical replication:

  • Perform at least three biological replicates per condition

  • Include technical replicates to assess method variability

  • Implement randomization of sample processing order to minimize batch effects

• Statistical analysis:

  • Use appropriate statistical tests for your experimental design

  • Consider non-parametric tests if assumptions of normality cannot be met

  • Implement power analysis to ensure sufficient sample size for detecting expected effect sizes

• Controls for genetic backgrounds:

  • When comparing strains, ensure matched genetic backgrounds except for the variation of interest

  • Consider complementation controls in deletion/mutation studies

  • For tagged versions, verify that tags don't interfere with normal function

• Standardization:

  • Maintain consistent sample preparation protocols across conditions

  • Use the same antibody lot for all comparisons when possible

  • Implement internal calibration curves for absolute quantification